INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Jasper Therapeutics, Inc. (JSPR) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Core Points - A shareholder class action lawsuit has been filed against Jasper Therapeutics, Inc. alleging materially false and misleading statements regarding the company's business and compliance policies [1] - The lawsuit claims that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its product briquilimab [1] - The allegations suggest that Jasper's business and financial prospects, as well as briquilimab's clinical and commercial prospects, were overstated [1] Legal Context - Shareholders who purchased Jasper shares between November 30, 2023, and July 3, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request lead plaintiff status in the lawsuit is November 18, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]